Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 128

Sort by

Sort Order Select

Journal Articles

Real-World Clinical Outcomes of Daratumumab-Based Regimens in Chinese Patients with Multiple Myeloma By Cytogenetic Risk: A Subgroup Analysis of the MMY4032 Study

Luqun Wang, Wei Yang, Ting Niu, Yafei Wang, Rong Fu, Yuping Zhong, Kaiyang Ding, Kai Sun, Baijun Fang, Hong Liu, Wenbin Qian, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu

Blood (2024) 144 (Supplement 1): 7874.

https://doi.org/10.1182/blood-2024-201134

Published: 2024

Journal Articles

A Single-Arm, Multi-Center, Retrospective Clinical Study of Cba Preconditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Acute Leukemia

Dingjun Zhuo, Xu Tan, Guo Chen, Yingying Ma, Maihong Wang, Siyu Chen, Qin Wen, Hong Liu, Cheng Zhang, Xi Zhang

Blood (2024) 144 (Supplement 1): 7120.

https://doi.org/10.1182/blood-2024-206275

Published: 2024

Journal Articles

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Blood (2024) 144 (Supplement 1): 304.

https://doi.org/10.1182/blood-2024-206377

Published: 2024

Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2024-204620

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

Combination of Olverembatinib and VP Regimen for Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Xu Tan, Guo Chen, Yingying Ma, Maihong Wang, Qin Wen, Hong Liu, Xi Zhang, Cheng Zhang

Blood (2024) 144 (Supplement 1): 1449.

https://doi.org/10.1182/blood-2024-206572

Published: 2024

Journal Articles

Venetoclax, Azacitidine, Combined with Low-Dose Cytarabine in Older Newly Diagnosed Acute Myeloid Leukemia：the Result of a Prospective, Multicenter, Open, Randomized Controlled Trials

Blood (2024) 144 (Supplement 1): 2902.

https://doi.org/10.1182/blood-2024-206513

Published: 2024

Journal Articles

Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial

Blood (2024) 144 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2024-200713

Published: 2024

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of AK117 (anti-CD47 monoclonal antibody) in Combination with Azacitidine in Patients with Treatment-Naïve Acute Myeloid Leukemia

Huafeng Wang, Qike Zhang, Qingliang Teng, Zhenyu Li, Hong Liu, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jie Jin

Blood (2023) 142 (Supplement 1): 4280.

https://doi.org/10.1182/blood-2023-180618

Published: 2023

Journal Articles

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Feifei Tang, Wen-Bing Duan, Xiao-Hong Liu, Sheng-Ye Lu, Xiao-Su Zhao, Ya-Zhen Qin, Jin-Song Jia, Jing Wang, Li-Zhong Gong, Qian Jiang, Zhao Ting, Hong-Xia Shi, Ying-Jun Chang, Xiao-Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2023-188657

Published: 2023

Journal Articles

Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Wen-Jing Yu, Ying Wu, Qi Chen, Xiaolu Zhu, Xu-Ying Pei, Jin-Song Jia, Jing Wang, Xiao-Su Zhao, Ying-Jun Chang, Yue-Yun Lai, Hong-Xia Shi, Guo-Rui Ruan, Ya-Zhen Qin, Xiao-Hong Liu, Xiao Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 1525.

https://doi.org/10.1182/blood-2023-184665

Published: 2023

Journal Articles

Real-World Analysis of Treatment Patterns and the Effectiveness and Safety Profile of Daratumumab-Based Regimens in Chinese Patients with Newly Diagnosed or Relapsed/Refractory Multiple Myeloma

Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu

Blood (2023) 142 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2023-180948

Published: 2023

Journal Articles

The OTUD1-Notch2-ICD axis orchestrates allogeneic T cell–mediated graft-versus-host disease

Qiao Cheng, Dong Wang, Xiaoxuan Lai, Yin Liu, Yibo Zuo, Wenli Zhang, Lei Lei, Jia Chen, Hong Liu, Ying Wang, Haiyan Liu, Hui Zheng, Depei Wu, Yang Xu

Blood (2023) 141 (12): 1474–1488.

https://doi.org/10.1182/blood.2022017201

Published: 2023

Includes: Supplemental data

Journal Articles

CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study

Wei Liu, Wenyang Huang, Rui Lv, Huimin Liu, Shuhua Yi, Hong Liu, Lulu Lv, Lugui Qiu, Jianxiang Wang, Dehui Zou

Blood (2022) 140 (Supplement 1): 4598–4599.

https://doi.org/10.1182/blood-2022-167104

Published: 2022

Journal Articles

Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4564–4565.

https://doi.org/10.1182/blood-2022-168610

Published: 2022

Journal Articles

Iron Chelation of Hetrombopag in Aplastic Anemia: A Post Hoc Analysis of a Phase II Study

Wenrui Yang, Xin Zhao, Guangsheng He, Hong Chang, Bing Han, Sujun Gao, Shunqing Wang, Tong Chen, Fei Li, Yi Wang, Xiaoyan Ge, Rong Fu, Zheng Ge, Yingmei Li, Hong Liu, Xinjian Liu, Miao Miao, Liansheng Zhang, Fengkui Zhang

Blood (2022) 140 (Supplement 1): 5809–5810.

https://doi.org/10.1182/blood-2022-164560

Published: 2022

Journal Articles

Disease Characteristics and Treatment Outcomes with HLX01: A Real-World Study in Patients with B-Cell Non-Hodgkin Lymphoma in China

Jun Ma, Li Zhiming, Wei Xu, Yao Liu, Weili Zhao, Zhihua Yao, Kaiyang Ding, Yudan Wu, Hong Liu, Wenyu Li, Yirong Jiang, Li'e Lin, Zhigang Peng, Zhimin Zhai

Blood (2022) 140 (Supplement 1): 12130–12132.

https://doi.org/10.1182/blood-2022-166137

Published: 2022

Journal Articles

The Clinical Outcomes and Genomic Landscapes of Acute Lymphoblastic Leukemia Patients with E2A-PBX1: A 10-Year Retrospective Study

Biqi Zhou, Xinran Chu, Hong Tian, Tianhui Liu, Hong Liu, Wei Gao, Suning Chen, Shaoyan Hu, Depei Wu, Yang Xu

Blood (2021) 138 (Supplement 1): 212.

https://doi.org/10.1182/blood-2021-146889

Published: 2021

Journal Articles

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia

Blood (2021) 137 (26): 3641–3655.

https://doi.org/10.1182/blood.2020007651

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment

Katharina Rothe, PhD, Xiaojia Niu, PhD, Min Chen, PhD, Rick Li, Sungeun Nam, Xiuyan Zhang, German Novakovskiy, Yehyeon Ahn, Shenshen Lai, Hong Zhang, PhD, Jun Yan, Hong Liu, Yun Zhao, PhD, Depei Wu, MDPhD, Yubin Ge, PhD, Wyeth W. Wasserman, Calvin K. Yip, Zaihui Zhang, PhD, Xiaoyan Jiang, MD PhD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-140595

Published: 2020

NARROW

Real-World Clinical Outcomes of Daratumumab-Based Regimens in Chinese Patients with Multiple Myeloma By Cytogenetic Risk: A Subgroup Analysis of the MMY4032 Study

A Single-Arm, Multi-Center, Retrospective Clinical Study of Cba Preconditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Acute Leukemia

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Combination of Olverembatinib and VP Regimen for Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Venetoclax, Azacitidine, Combined with Low-Dose Cytarabine in Older Newly Diagnosed Acute Myeloid Leukemia：the Result of a Prospective, Multicenter, Open, Randomized Controlled Trials

Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial

A Phase 1b Study Evaluating the Safety and Efficacy of AK117 (anti-CD47 monoclonal antibody) in Combination with Azacitidine in Patients with Treatment-Naïve Acute Myeloid Leukemia

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Real-World Analysis of Treatment Patterns and the Effectiveness and Safety Profile of Daratumumab-Based Regimens in Chinese Patients with Newly Diagnosed or Relapsed/Refractory Multiple Myeloma

The OTUD1-Notch2-ICD axis orchestrates allogeneic T cell–mediated graft-versus-host disease

CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study

Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Iron Chelation of Hetrombopag in Aplastic Anemia: A Post Hoc Analysis of a Phase II Study

Disease Characteristics and Treatment Outcomes with HLX01: A Real-World Study in Patients with B-Cell Non-Hodgkin Lymphoma in China

The Clinical Outcomes and Genomic Landscapes of Acute Lymphoblastic Leukemia Patients with E2A-PBX1: A 10-Year Retrospective Study

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia

Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only